I researched patent issuance dates for the current technologies offered by Nanologix with the intent being to demonstrate that in my opinion the calendar for viable technology dates more from 2013 for the petri packaging technology and from 2015 for the N-Assay. They began selling petri packs in 2012 and N-Assay on a customization project in 2016. Prior to those technologies they had the Hydrogen Bioreactor technology, which doesn't appear to have gone anywhere; the BNC and BNF technologies, which also went nowhere; and the BNP, which appears to have some interest when it comes to Anthracis and Tuberculosis, but not much else.
I believe the early technology going back ten years was legacy technology and subsequently found to be valueless, and the two later technologies invented by the CEO were a major change of direction for the company which will enrich all of us who are shareholders.
The petri flat packaging should have good appeal to markets worldwide, and the N-Assay should also have very broad appeal around the world.
As for a ten year period being cited as indicative of lack of management capabilities, I must opine that for them to have spent much time on development of the legacy technologies would have meant that any of you who were invested from 2007 and through the subsequent years until the undoubted end of Nanologix would have meant that you would have lost everything and I and others who came later would have never invested because there wouldn't have been a company to invest in.
So I view management as far from lacking.
Most of this comes from information I have gleaned through due diligence and in my quest to update this website.
EI
